We are live on ! Find out more
BVXVW

BiondVax Pharmaceuticals Ltd.
BVXVW

Delisted

BVXVW was delisted on the 13th of May, 2020.

Back to rankings

4 hedge funds and large institutions have $130K invested in BiondVax Pharmaceuticals Ltd. in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 2 → 4 (+2)

29% more capital invested

Capital invested by funds: $101K → $130K (+$29K)

Holders
4
Holders Change
+2
Holders Change %
+100%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$21.3K
2
UBS Group
UBS Group
Switzerland
+$1.7K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CH
1
CVI Holdings
Delaware
$92K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$21K +$21.3K +16,362 New
VIA
3
Vantage Investment Advisors
Pennsylvania
$15K – – –
UBS Group
4
UBS Group
Switzerland
$2K +$1.7K +1,303 New

BVXVW Hedge Fund Activity: Q2 2018 in Review

4 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in BiondVax Pharmaceuticals Ltd. (BVXVW) for Q2 2018, worth a combined $130K — up 29% from $101K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BVXVW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $21.3K.

  • 4 institutional investors held BiondVax Pharmaceuticals Ltd. (BVXVW) as of Q2 2018, up from 2 in Q1 2018.
  • Funds reported $130K of BiondVax Pharmaceuticals Ltd. stock for Q2 2018, up 29% quarter-over-quarter.
  • 2 funds opened new BiondVax Pharmaceuticals Ltd. positions in Q2 2018 and 0 closed out, a net change of +2 holders.
  • The largest BiondVax Pharmaceuticals Ltd. buyer in Q2 2018 was Susquehanna International Group, an estimated $21.3K added.

Based on aggregated 13F filings for Q2 2018.